New quinolones - A fresh answer to the pneumococcus

Journal of Antimicrobial Chemotherapy

Volumn 46, Issue 6, 2000, Pages 869-872

  Cubbon, M D ^a   Masterton, R G ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; BACTERIAL DNA; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINAFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; GATIFLOXACIN; GREPAFLOXACIN; IMIPENEM; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; NEW DRUG; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; SPARFLOXACIN; TEMAFLOXACIN; TROVAFLOXACIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL MENINGITIS; COMMUNICABLE DISEASE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG POTENCY; DRUG RESEARCH; HEART ARRHYTHMIA; HEMOLYSIS; HUMAN; HYPOGLYCEMIA; KIDNEY FAILURE; LIVER TOXICITY; LONG QT SYNDROME; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PHOTOTOXICITY; SINUSITIS; STRAIN DIFFERENCE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

EID: 0034532258     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/46.6.869     Document Type: Article

References (51)

1. Community-acquired pneumonia
2. Acute community-acquired sinusitis
3. Bacterial meningitis in the United States in 1995. Active surveillance team
4. Acute exacerbations of chronic bronchitis: An international comparison
5. Unusual manifestations of invasive pneumococcal infection
6. Multiple antibiotic resistance in Streptococcus pneumoniae
7. New quinolones: Their role in clinical practice
8. Infectious complications with respiratory pathogens despite ciprofloxacin therapy
9. Lower respiratory tract infection therapy - The role of ciprofloxacin
10. Will pneumococci put quinolones in their place?
11. In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates
12. In-vitro activity of levofloxacin (l-ofloxacin), ofloxacin and ciprofloxacin against clinical isolates of Streptococcus pneumoniae obtained in England and Wales
13. A comparison of the activity of ciprofloxacin and levofloxacin with other agents against respiratory tract pathogens
14. Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract
15. Pharmacokinetics and pharmacodynamics of fluoroquinolones
16. The etiology of respiratory tract infections and the antibacterial activity of fluoroquinolones and other oral antibacterial agents against respiratory pathogens
17. Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections
18. Comparative activity of fluorinated quinolones in acute and subacute Streptococcus pneumoniae pneumonia models: Efficacy of temafloxacin
19. Moxifloxacin in the therapy of experimental pneumococcal meningitis
20. Protective effect of trovafloxacin, ciprofloxacin and ampicillin against Streptococcus pneumoniae in a murine sepsis model
21. Epidemiology and mechanisms of resistance among respiratory tract pathogens
22. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro
23. Bactericidal effects of levofloxacin in comparison with those of ciprofloxacin and sparfloxacin
24. Sparfloxacin vs ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis: A multicenter, double-blind, randomized, comparative study
25. Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: Results of a randomized, double-blind study
26. Randomized, double-blind study of grepafloxacin versus amoxycillin in patients with acute bacterial exacerbations of chronic bronchitis
27. Comparative safety and efficacy of sparfloxacin in the treatment of acute exacerbations of chronic obstructive pulmonary disease: A double-blind, randomized, parallel, multicentre study
28. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis
29. Randomized, double-blind study of short-course (5 day) grepafloxacin versus 10 day clarithromycin in patients with acute bacterial exacerbations of chronic bronchitis
30. Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia
31. Oral empiric treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin
32. A multicentre, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia
33. Sparfloxacin for the treatment of community-acquired pneumonia: A pooled data analysis of two studies
34. Treatment of community-acquired pneumonia: A randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin
35. Once-daily sparfloxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults
36. Sparfloxacin versus cefuroxime axetil in the treatment of acute purulent sinusitis
37. A comparison of levofloxacin QD and amoxycillin-clavulanate TID for the treatment of acute bacterial sinusitis
38. Levofloxacin in the empirical treatment of patients with suspected bacteraemia/sepsis: Comparison with imipenem/cilastatin in an open, randomized trial
39. Evaluation of moxifloxacin, a new 8-methoxyquinolone, for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits
40. Pharmacodynamics of trovafloxacin in experimental pneumococcal meningitis: Basis for dosage selection in children with meningitis
41. Comparative tolerability of the newer fluoroquinolone antibacterials
42. Structure-activity and structure-side effect relationships for the quinolone antibacterials
43. Quinolone-induced QT interval prolongation: A not-so-unexpected class effect
44. Safety profile of grepafloxacin compared with other fluoroquinolones
45. Tolerability of fluoroquinolone antibiotics. Past, present and future
46. Optimizing economic outcomes in antibiotic therapy of patients with acute bacterial exacerbations of chronic bronchitis
47. Growth in the use of antibiotics in the community in England and Scotland in 1980-93
48. Resistance in hospitals: Implications for empiric choice of therapy
49. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
50. Emergence of fluoroquinolone resistance among multiple resistant strains of Streptococcus pneumoniae in Hong Kong
51. Relative potential for selection of fluoroquinolone-resistant Streptococcus pneumoniae strains by levofloxacin: Comparison with ciprofloxacin, sparfloxacin and ofloxacin